Novartis to add fourth US radioligand therapy manufacturing facility in Winter Park, Florida
The built-for-purpose, state-of-the-art facility represents another milestone in our $23 billion US infrastructure investment announced in April 2025, further expanding manufacturing capabilities to meet growing demand for cutting-edge cancer treatments.
Discover our medicines
See how our innovative medicines are addressing society's greatest health challenges.
Commitment to patients
From research and development to expanding access, uncover our commitment to improving people's lives.
Inspired by purpose
Learn about our people and culture, and how we're driven by our mission to reimagine medicine.
Latest News
